Skip to main content

stock

AIM · AIM ImmunoTech Inc.

What AIM ImmunoTech Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live AIM price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on AIM.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
30,442,139 as of 2026-08-07 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-11724.2%
Net
-15021.1%

Returns

ROE
-184.3%
ROA
-112.1%

Health

Current ratio
2.1x
Debt/equity
0.5x

Deep value

NCAV
$5.45M
NCAV per share
$0.18
Price/NCAV
Locked
NNWC
$4.91M
NNWC per share
$0.16
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$26,000—Gross profit: unreported by this company.-$3.51M-$3.79M
10-Q filed 2026-08-07
2026-03-31$22,000—Gross profit: unreported by this company.-$2.23M-$3.02M
10-Q filed 2026-08-07
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31$21,000—Gross profit: unreported by this company.-$2.95M-$4.17M
DEF 14A filed 2026-09-30
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$26,000—Gross profit: unreported by this company.-$2.45M-$3.28M
10-Q filed 2025-11-17
2025-06-30$25,000—Gross profit: unreported by this company.-$2.65M-$2.79M
10-Q filed 2026-08-07
2025-03-31$16,000—Gross profit: unreported by this company.-$3.62M-$3.71M
10-Q filed 2026-08-07
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31$45,000—Gross profit: unreported by this company.-$5.86M-$5.97M
DEF 14A filed 2026-09-30
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$35,000—Gross profit: unreported by this company.-$4.49M-$3.70M
10-Q filed 2025-11-17
Assets
$12.73M
Equity
$7.74M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$88,000-$11.66M-$13.96M—
2024-12-31$170,000-$19.77M-$17.32M-$14.91M
2023-12-31$202,000-$31.92M-$28.96M—
2022-12-31$141,000-$19.92M-$19.45M-$16.19M
2021-12-31$135,000-$18.84M-$19.13M-$14.01M
2020-12-31$163,000-$15.15M-$14.40M-$10.39M
2019-12-31$140,000-$12.44M-$9.40M-$9.13M
2018-12-31$367,000-$11.50M-$9.83M-$10.69M
2017-12-31$437,000-$11.42M-$8.26M-$7.96M
2016-12-31$92,000-$13.80M-$7.50M-$7.54M

Company filings

9 offering filings in 12 months · since Wed Jun 10

events

  • Material agreement, Unregistered share sale

    Material agreementUnregistered share sale
    Sep 148-K
  • Material agreement, Unregistered share sale

    Material agreementUnregistered share sale
    Sep 108-K
  • Material agreement, Agreement ended, Unregistered share sale

    Material agreementAgreement endedUnregistered share sale
    Sep 48-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Aug 118-K
  • Results

    Results
    Aug 108-K
  • Material agreement, Item 5.08

    Material agreementItem 5.08
    Aug 68-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

  • Equels Thomas K

    CEO & President, Director

    Buy$4,992

    Sep 18, 8:30 AM ET

  • Equels Thomas K

    CEO & President, Director

    Buy$2,310

    Sep 17, 12:01 PM ET

  • Equels Thomas K

    CEO & President, Director

    Buy$4,862

    Sep 16, 9:15 AM ET

  • Equels Thomas K

    CEO & President, Director

    Buy$1,292

    Sep 15, 4:30 PM ET

All insider trades for AIM

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named AIM, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about AIM.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about AIM.

nakagai

Signals on AIM come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the AIM board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

AIM ImmunoTech Inc. (AIM): SEC filings, financials and insider trades · Nakagai